Skip to main content
DAEWOONG PHARMA logo

DAEWOONG PHARMA — Investor Relations & Filings

Ticker · 069620 ISIN · KR7069620003 KO Manufacturing
Open in API
Filings indexed 380 across all filing types
Latest filing 2024-08-09 Earnings Release
Country KR South Korea
Listing KO 069620

About DAEWOONG PHARMA

http://crm.daewoong.co.kr/eng/main

Daewoong Pharma is an R&D-centric pharmaceutical company specializing in the development, manufacturing, and commercialization of medical products. The company's portfolio encompasses prescription drugs, with a focus on gastrointestinal and endocrine therapies, alongside biologics, healthcare products, and active pharmaceutical ingredients (APIs). A core tenet of its business model is 'Open Collaboration,' actively seeking partnerships with academic and industry entities to foster innovation. Daewoong Pharma's research efforts are directed towards breakthrough therapies, utilizing advanced drug delivery technologies and expertise in biologics. The company also offers integrated formulation and manufacturing services, supporting partners from initial development to commercial production.

Recent filings

Filing Released Lang Actions
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for Daewoong Pharmaceutical for the second quarter of 2024. It provides key financial highlights such as revenue, operating profit, and net income, and explicitly states that these are preliminary figures (잠정치) that have not been audited. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results. Q2 2024
2024-08-09 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical regarding the approval of a Phase 3 clinical trial (IND) for its drug 'Fexuclue' in China. This type of disclosure, which reports significant business developments or material events to the stock exchange (KRX), falls under the category of general regulatory announcements for material corporate events.
2024-08-05 Korean
타인에대한채무보증결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Daewoong Pharmaceutical regarding a 'Decision on Debt Guarantee for Others' (타인에대한채무보증결정). This is a specific type of corporate disclosure required by capital market regulations in South Korea, detailing financial guarantees provided to subsidiaries. Since it does not fit into specific categories like M&A, dividends, or share repurchases, and is a standard regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2024-07-15 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical regarding a 'Single Sales/Supply Contract' amendment. It details a change in the counterparty for a previously disclosed contract (DWJ108U depot injection). Since this is a formal regulatory disclosure of a material contract amendment filed with the financial authorities, and it does not fit into specific categories like M&A (which usually refers to corporate takeovers) or other specialized categories, it is best classified as a general Regulatory Filing (RNS).
2024-07-04 Korean
지속가능경영보고서등관련사항(자율공시)
Environmental & Social Information Classification · 100% confidence The document is a regulatory filing (voluntary disclosure) announcing the publication of the company's '2024 Sustainability Report'. It provides metadata about the report, such as the reporting period, verification body, and a link to the company website where the full report can be accessed. Per the 'Menu vs Meal' rule, since this is a short announcement document directing users to the actual report, it is classified as a Report Publication Announcement (RPA).
2024-06-27 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical regarding the approval of a Phase 3 clinical trial (IND) for a diabetes drug. It is a standard 'Major Management Matter' disclosure filed with the Korea Exchange (KRX). Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a formal regulatory announcement of a business event, it falls under the 'Regulatory Filings' category.
2024-06-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.